Company Overview and News
BRUSSELS, April 17 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
WASHINGTON — President Trump continued a sweeping remake of the Federal Reserve’s leadership on Monday by nominating Richard Clarida, a Treasury official in the administration of President George W. Bush, for the Fed’s second-ranking job.
BRUSSELS, April 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
London:Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.
Mumbai: Metropolis Healthcare Ltd, an operator of medical diagnostic centers backed by Carlyle Group LP, is considering an initial public offering (IPO) to raise about Rs1,500 crore ($230 million) as it seeks acquisitions.
They're all cumulative, and 3 of 4 are selling below their $25 call value - the 4th is at $25.03.
REUTERS: No. 2 U.S. nursing home chain HCR ManorCare Inc won court approval on Friday for a plan to exit a US$7.1 billion Chapter 11 bankruptcy by transferring ownership to its landlord, Quality Care Properties Inc .
(Reuters) - No. 2 U.S. nursing home chain HCR ManorCare Inc won court approval on Friday for a plan to exit a $7.1 billion Chapter 11 bankruptcy by transferring ownership to its landlord, Quality Care Properties Inc (QCP.N).
REUTERS: No. 2 U.S. nursing home chain HCR ManorCare Inc heads to court on Friday to seek approval for a plan to exit a US$7.1 billion Chapter 11 bankruptcy under the ownership of the real estate investment trust whose steep rents lent to its financial demise.
April 11 (Reuters) - The Ontario Teachers' Pension Plan will buy a 40 percent stake in European Camping Group (ECG) from U.S. buyout firm Carlyle Group LP and Montefiore Investment, the Canadian pension fund said here on Wednesday.
AMSTERDAM, April 10 (Reuters) - Varo Energy BV said on Tuesday it had decided not to proceed with plans for a flotation on the Euronext stock exchange in Amsterdam, citing poor market conditions.
Wall Street analysts expect The Carlyle Group (CG) to see EPS (earnings per share) of $0.54 in 1Q18, reflecting a substantial decline YoY (year-over-year). They gave a high estimate of $0.71 and a low estimate of $0.22. EPS are expected to fall mainly due to outflow from debt markets impacting its global credit segment.
Markets have grown well-versed at disregarding structural issues. I'm still amazed at what the marketplace was willing to ignore throughout the mortgage finance bubble period: A doubling of mortgage credit in just about six years; California's housing market out of control by 2005; $1.0 trillion of subprime CDS in 2006; the unprecedented growth in leveraged securities holdings and so on. Unrelenting trade and current account deficits.
LONDON (Reuters) - Sovereign investors participated in deals worth a record $42 billion in the first quarter, led by Singapore fund GIC’s involvement in the two biggest transactions, which accounted for $29.6 billion combined.
City software firm Fidessa has pushed its vote on a £1.4bn takeover by Swiss group Temenos to the last possible moment while it considers potentially better offers from rivals.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET